The company’s performance reflects a broader downturn in the agricultural sector, with volume falling 10 percent due to lower diamide partner orders and softening demand for legacy products in North America. Beyond the volume decline, pricing pressures further hampered results, dropping 7 percent as the firm navigated a challenging macro environment. While the company achieved an adjusted EBITDA of $153 million, this figure represents a 26 percent decrease compared to the same period in 2025.
Following a strategic review, Chairman and CEO Pierre Brondeau confirmed that the company is focusing on debt reduction and operational efficiency. FMC has secured roughly $1 billion in proceeds through targeted moves, including the sale of its India commercial business, a rimisoxafen licensing agreement with Corteva, and a property sale in Newark, Delaware. Looking ahead, the company expects a return to year-over-year growth in the fourth quarter, though its revised full-year outlook anticipates a 23 percent decline in adjusted EBITDA at the midpoint.
Comments (0)
No comments yet. Be the first!